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What Is the Strength of Evidence for
Heart Failure Disease-Management Programs?
Alexander M. Clark, PHD,* Lori A. Savard, BSC,* David R. Thompson, PHD†
Edmonton, Alberta, Canada; and Leicester, United Kingdom
Heart failure (HF) disease-management programs are increasingly common. However, some large and recent
trials of programs have not reported positive findings. There have also been parallel recent advances in reporting
standards and theory around complex nonpharmacological interventions. These developments compel reconsid-
eration in this Viewpoint of how research into HF-management programs should be evaluated, the quality, speci-
ficity, and usefulness of this evidence, and the recommendations for future research. Addressing the main deter-
minants of intervention effectiveness by using the PICO (Patient, Intervention, Comparison, and Outcome)
approach and the recent CONSORT (Consolidated Standards of Reporting Trials) statement on nonpharmacologi-
cal trials, we will argue that in both current trials and meta-analyses, interventions and comparisons are not suf-
ficiently well described; that complex programs have been excessively oversimplified; and that potentially salient
differences in programs, populations, and settings are not incorporated into analyses. In preference to more gen-
eral meta-analyses of programs, adequate descriptions are first needed of populations, interventions, compari-
sons, and outcomes in past and future trials. This could be achieved via a systematic survey of study authors
based on the CONSORT statement. These more detailed data on studies should be incorporated into future
meta-analyses of comparable trials and used with other techniques such as patient-based outcomes data and
meta-regression. Although trials and meta-analyses continue to have potential to generate useful evidence, a
more specific evidence base is needed to support the development of effective programs for different popula-
tions and settings. (J Am Coll Cardiol 2009;54:397–401) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.051o
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ahe development of disease-management programs for the
arge and vulnerable population with heart failure (HF)
rought important multidisciplinary support to patients.
owever, a number of recent trials (1– 6) have found no
r limited benefits from programs. In the context of new
ONSORT (Consolidated Standards of Reporting Tri-
ls) reporting requirements (7) and theoretical advances
8–10), it is timely to address how current research into
F-management programs should be evaluated; the quality,
pecificity, and usefulness of current evidence; and useful
irections for future research.
ow Should Program Trials Be Evaluated?
hat are fair criteria with which to evaluate the quality of
xisting program trials? There is a strong case for drawing
n the reporting requirements of the CONSORT statement
7) for nonpharmacological trials (Table 1). Published trials
rom the *University of Alberta, Edmonton, Alberta, Canada; and the †Department
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Manuscript received March 1, 2009; revised manuscript received April 6, 2009,
ccepted April 14, 2009.f programs predate these new reporting requirements but
ather than introducing novel principles, the new CONSORT
tatement (7) codifies well-established principles of design
nd appraisal. As expressed in the acronym PICO (11), the
ffectiveness of any intervention is determined by the
haracteristics of the intervention (I) and the population
eceiving it (P). In trials, apparent effectiveness is also
nfluenced by what the intervention is compared with (C),
hat outcomes are measured, and the quality and timing of
hese measurements (O) (11). As the 4 main determinants
f treatment effectiveness, design weakness or vague report-
ng in any one of these aspects extensively impacts study
uality.
The CONSORT statement (7) also recognizes that
onpharmacological trials are different than pharmacologi-
al trials. Recent theoretical work acknowledges the inher-
nt complexity of health services interventions, for example,
n systems (10) and contextual effects (12). These advances
re evident in trial development frameworks (8,9), policy
13), and evaluation (14). For example, the American Heart
ssociation (AHA) developed a taxonomy of HF-
anagement programs that classified programs in structure
nd design around at least 8 parameters, each in at least 4
ifferent ways (15).
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tion, there is a growing realization
that decision and policymakers
need specific and context-responsive
evidence (16). Knowledge is needed
not only of whether there is a
general likelihood that an entire
genre of programs will work in
any setting but the size of likely
benefit in a particular setting from
programs with specified compo-
nents, delivery mechanisms, and
ersonnel (10). Hence, rather than threatening the future
xistence of HF-management programs, considering evidence
n the light of recent advances addresses essential elements of
esearch design, theory, and knowledge translation.
vidence From Current Trials
hat is the quality of existing evidence from program trials?
here are many complex issues to address in the design of
randomized trial (17), but both CONSORT (7) and
ICO suggest some fundamental aspects require attention.
hat interventions are studied? Interventions should be
escribed comprehensively in terms of content, compo-
ents, providers, and standardization procedures (7) because
hese dimensions could influence treatment effects (7,8,10).
oncerns have been raised that, in current trials, programs
re poorly described (18–22), and elements are seldom
ustified (15,23). There is a tendency to categorize programs
ased on a single or small number of macro characteristics
such as the main intervention setting or provider), although
Abbreviations
and Acronyms
AHA  American Heart
Association
CONSORT  Consolidated
Standards of Reporting
Trials
HF  heart failure
PICO  Patient,
Intervention, Comparison,
Outcome
eporting Standards for Intervention Componentsrom CON ORT nd Modified CONSORT foronpharmacological Treatments
Table 1
eporting Standards f r Interve tion Components
From CONSORT and Modified CONSORT for
Nonpharmacological Treatments
Recommendations
for Reporting Standard CONSORT
CONSORT for
Nonpharmacological Trials
Item 4 Precise details of the
interventions
intended for each
group and how
and when they
were actually
administered
Precise details of both the
experimental treatment
and comparator
Item 4A Description of the different
components of the
interventions and, where
applicable, description
of the procedure for
tailoring to individual
participants
Item 4B Details of how
interventions were
standardized
Item 4C Details of how adherence
of care providers with
the protocol was
assessed or enhancedcONSORT  Consolidated Standards of Reporting Trial.any other characteristics may be important (15,19,23).
ide diversity in trials exists around these potentially
nfluential characteristics, including follow-up period, drug
herapy optimization, intervention content, and mode(s) of
rovision (20,22). Other unknown or previously undocu-
ented dimensions of interventions and their settings may
lso influence outcomes (8,10,24).
o what are interventions compared? Both PICO and
ONSORT require that the care that comparison groups
eceive should be described comprehensively (7). Systematic
eview has identified that trials of programs currently do not
etail sufficiently what “usual” or “routine” care comparison
roups received (20,22,25,26). This lack of detail creates
ias because pharmacological care for HF varies widely over
lace, time, and sector (27,28). Prescription rates of key
harmacotherapies have differed historically and are influ-
nced by geographic location (28), the availability of spe-
ialists (29,30), and the aggressiveness of management
31,32). These differences are crucial because any apparent
ffect (or lack thereof) in a trial could be attributed equally
o variations in usual care as to the intervention (7).
hat is measured and how? More research is needed into
he long-term effects of programs. Some trials with long-
erm follow-up show sustained benefits (33,34), but others
o not (35). Most trials follow patients up for 9 to 12
onths (27,36), but this duration may be insufficient to
emonstrate impact on mortality (37), or patients may be
eadmitted before receiving the full effect of a program (1).
What should be concluded from current trials? Taking
ccount of the trends in design and reporting described,
here remains uncertainty regarding the direction and size of
hort- and long-term benefits likely to arise from different
ypes of programs in different populations and settings. This
s not to say that such benefits do not exist. However, to
onclude that all or any types of programs will be as effective
n all settings assumes a similarity or irrelevance of popula-
ion, intervention, comparison, and context that is not
ubstantiated by current data or theory.
uilding a Better Trial Evidence Base
ore randomized trials of well-described interventions with
onger-term follow-up periods are needed. To evaluate the
ffects of different types of programs in particular popula-
ions and settings, precise details should be provided of care
or both the intervention and comparison groups, how the
ntervention was standardized across settings and personnel,
nd the degree and assessment of adherence of the providers
f the intervention to the protocol (7). To identify the
ultiple dimensions of a complex intervention and the ways
t is intended to improve outcomes, future trials should be
eveloped by the use of frameworks designed to support the
esign and evaluation of complex interventions (8,9). The
ONSORT standards (7) and AHA taxonomy (15) should
e used to incorporate reporting standards into design, data
ollection, and other trial documentation. Adjunct qualita-
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July 28, 2009:397–401 HF Disease-Management Programsive studies should be used to better understand “what works
or whom, when and why” (19,24) via exploration of the
echanisms of effect of interventions and the moderating
ffects of population and context (8,10,19).
vidence From Current Meta-Analyses
rials of programs form complex, diverse, and often poorly
escribed evidence, but this has not deterred frequent
eta-analysis (20,22,26,36–46).
opulations: sample composition, size, and study
eighting. Reflecting the trials themselves, the sample size
n the majority of systematic reviews is comparatively small
22,42), with total sample sizes rarely reaching 5,000 (36,37)
nd most being around 2,000 (22,37–39,42,44,46). Size is
ikely to be related to the degree of focus of the review, but
maller sample size can lead to false conclusions due to
andom error (47). Also, because few reviews include 15
rials (22,42,46,48), pooled estimates in meta-analysis are
hen heavily influenced by a small number of large single
rials (Table 2) (49).
No existing reviews pool data on outcomes by sex or age,
nd many do not identify the sex of the population that
ooling is based on (22,37,38,40,42,44). This reflects in-
omplete reporting in the trials, but treatment and outcomes
o vary by sex (50,51). This omission also prevents suba-
alysis to determine whether variation occurs in programs
52), an important step when studies have diverse popula-
ions (53).
nterventions: comparisons and heterogeneity. In meta-
nalysis, a lack of comprehensive descriptions of interven-
ions and usual care makes it problematic to decide if and
hen trial findings should be pooled or to pinpoint the
ource of variations (54) because there must be sufficient
imilarity between trials for data to be pooled (55). Those
20,22,25,26) undertaking meta-analysis of programs have
cknowledged a shortage of information about interventions
n trial reports. However, few (22) have fully recognized the
onstraining implications this has on the ability to pool data.
That said, when viewed as complex, differences between
ealth services interventions abound (56). Heterogeneity
ighest Trial Weightings in Selected Meta-Analysesf Heart Failure Disease-Managem nt ProgramsTable 2 Highe t Trial Weightings in Selected Meta-Analysesof Heart Failure Disease-Management Programs
Review (Ref. #)
Highest Weighting of
Individual Trial, %
Clark et al. (42) 39.73
Gonseth et al. (38) 68.18
21.55
Gwadry-Sridhar et al. (39) 19.6
25.7
Holland et al. (5) 9.49
10
Roccaforte et al. (45) 10.61
Taylor et al. (22) 17.2
40.9
34.5 (Various subanalyses)hesulting from these differences is detectable not only via
tatistical testing but also by examining the characteristics of
opulations, interventions, and outcomes (57). Current
eviews focus overwhelmingly on statistical heterogeneity
ith notable exceptions (22,40). Clinical and methodolog-
cal heterogeneity arising from differences in population,
rograms, and methods remain comparatively ignored (58).
his is unfortunate because exploring sources of clinical and
ethodological heterogeneity is arguably more important
han testing for statistical heterogeneity (57,58).
Reflecting the diversity of trials included in reviews, many
eta-analyses (20,26,36–38,40,41,44–46) report high sta-
istical heterogeneity. Rather than merely commenting on
he existence of statistical heterogeneity, it is more impor-
ant to take it into account in the Methods and Conclusions
ections (57,58) and explain or investigate why differences
ccur (56). This is hampered by the lack of comprehensive
nd detailed descriptions of trials and control groups. Even
ith strong evidence of statistical heterogeneity, some
eviews (41,59) nevertheless pool data to produce summa-
ive estimates and make conclusions thereon.
easurements: duration and follow-up. Duration of in-
ervention and length of follow-up are not consistently
eported in reviews and few reviews report data in both areas
36,37,40,45,46), which again raises the possibility that
tudies with short-term follow-up will not identify actual
hanges in mortality and morbidity.
ow should future programs be evaluated? Given the
omplex nature of programs and the need for specific
vidence, how should programs be evaluated in the future by
he use of systematic review? Meta-analysis has had success
n allowing the benefits of cardiovascular therapies to
merge from inconsistent results from trials and reviews
60). However, when used simplistically, inappropriately or
ith a biased sample of studies, meta-analysis can be a
isplaced attempt to create certainty where none such can
xist (61).
New trial findings of programs should not be incorpo-
ated de facto into additional general meta-analyses of
rograms to calculate amended overall effect sizes (62).
eta-analysis is dependent on comprehensive and accurate
nformation on past trials. There is an urgent need for a
omprehensive and systematic survey of the authors of
xisting trials, drawing on CONSORT (7) and the AHA
axonomy (15), around the key population, intervention,
omparison, and outcomes characteristics missing from
xisting published trials. Although most published trials of
ealth services interventions do not describe interventions
dequately (63), trial authors often record many details on
nterventions beyond those included in publications (63).
his would support future meta-analyses by adding impor-
ant and rigorous descriptive detail of past trials.
Meta-analyses can be too occupied with seeking “head-
ine” summative effect sizes (61,64) by pooling data from
ncomparable trials to increase sample size and the likeli-
ood of a significant effect (61,64). This assumes similar
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HF Disease-Management Programs July 28, 2009:397–401ffect sizes in different types of programs, populations, and
ettings (24); does not explain inconsistent trial results (24);
nd provides findings that are too general to be useful for
ractice and policy (12). Recognizing the complexity of
rograms (15), it is inappropriate to focus new meta-
nalyses on whether programs en masse work or do not
ork for all populations and settings (19). As has occurred
n drug-eluting stents, strenuous efforts are needed to
pecify benefits and costs of programs of different types in
ifferent settings and subpopulations (64), including
omen, different health systems, patients 80 years of age,
nd patients in rural settings. It should be a priority to
erform meta-analyses based on patient-based data rather
han published results; this may allow more rapid under-
tanding of the effects of comparable programs on different
ubpopulations (65).
Meta-analysis of any complex health services intervention
aces the challenge of determining at which point a trial
ecomes sufficiently incomparable to pool with other stud-
es. The multitude of known and unknown differences in a
omplex intervention means that differences and heteroge-
eity are inevitable (66). Findings should only be pooled in
uture meta-analyses when programs share similar features
hat are likely to have an impact on outcomes. This accepts
he inevitability of heterogeneity but accepts this providing
t occurs around features that are unlikely to be associated
ith the treatment effects or program costs (66).
To inform this, more evidence is needed regarding what
rogram characteristics are most likely to determine pro-
ram effects. A number of existing reviews have attempted
o do this in relation to effectiveness (22,26,27), but these
ttempts are constrained by inadequate reporting in trials.
he potential for bias arising from the effects of a small
umber of trials could also be addressed in pooling by
eighting trials by quality (49). With improved data on
xisting trials, knowledge of which characteristics are most
nfluential should accrue. Meta-regression offers a promis-
ng means to identify which characteristics of programs
redict better outcomes (27) and could inform subanalyses
nd sensitivity analyses.
eprint requests and correspondence: Dr. Alexander M.
lark, University of Alberta, Level 3, Clinical Sciences Build-
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